Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
According to Ipsen S.A.'s latest financial reports the company's current revenue (TTM) is $3.59 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
---|---|---|---|---|---|
2023 | $3.59 B | $2.97 B | $1.24 B | $821.71 M | $700.32 M |
2022 | $3.43 B | $2.86 B | $1.23 B | $765.52 M | $704.88 M |
2021 | $2.99 B | $2.51 B | $1.15 B | $858.01 M | $702.71 M |
2020 | $2.92 B | $2.39 B | $1.01 B | $577.19 M | $595.55 M |
2019 | $2.93 B | $2.4 B | $938.43 M | $-37,819,718 | $-59,663,865 |
2018 | $2.55 B | $2.06 B | $726.18 M | $538.17 M | $423.3 M |
2017 | $2.19 B | $1.77 B | $529.15 M | $404.28 M | $295.93 M |
2016 | $1.82 B | $1.43 B | $420.58 M | $325.92 M | $245.5 M |
2015 | $1.65 B | $1.29 B | $382.11 M | $260.93 M | $206.38 M |
2014 | $1.45 B | $1.11 B | $307.77 M | $226.37 M | $166.82 M |
2013 | $1.39 B | $1.06 B | $273.65 M | $218.98 M | $165.78 M |
2012 | $1.39 B | $1.11 B | $267.94 M | $130.69 M | $-32,050,037 |
2011 | $1.34 B | $1.07 B | $303.84 M | $44.96 M | $460.79 K |
2010 | $1.27 B | $1.02 B | $289.64 M | $136.28 M | $103.98 M |
2009 | $1.21 B | $950.47 M | $235.44 M | $181.82 M | $170.8 M |
2008 | $1.13 B | $889.18 M | $259.5 M | $196.88 M | $160.48 M |
2007 | $1.08 B | $863.69 M | $284.27 M | $224.81 M | $164.18 M |
2006 | $936.45 M | $739.33 M | $269.62 M | $201.79 M | $156.5 M |
2005 | $857.15 M | $664.97 M | $206.36 M | $168.46 M | $129.58 M |
2004 | $786.81 M | $595.2 M | $175.43 M | $125.68 M | $90.2 M |